RXRX RECURSION PHARMACEUTICALS, INC.

CIK 0001601830 50 ready 8-Ks latest June 18, 2026, 5:04 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 18, 2026, 5:04 PM ET

Top materiality 0.85

Event mix other_material ×19 · leadership ×8 · m_and_a ×8

Sentiment 17 pos · 3 neg · 30 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for RXRX

Highest-materiality recent filing

Recursion completes Exscientia acquisition; issues 102M shares, names new CFO

November 20, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 2.01 item 5.02 item 7.01 item 8.01 item 9.01 item 6.01 ◈ executive_change ×3◈ M&A Transactions

Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
Exscientia ADSs (EXAI) delisted from Nasdaq; equity awards converted to Recursion options/RSUs using Exchange Ratio.

Read filing →

June 18, 2026, 5:04 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Recursion Pharma 2026 annual meeting elects directors, approves exec compensation, ratifies auditor

Elected Najat Khan, Ph.D. and Franziska Michor, Ph.D. as Class II directors until 2029 annual meeting.
May 6, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Recursion Q1 net loss narrows to $117.5M; REC-1245 safety data positive, REC-4539 dosed

Net loss of $117.5M vs $202.5M YoY; revenue $6.5M, down 56% YoY on lower Roche milestone phasing.
April 30, 2026, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Recursion founder & Chair Chris Gibson will not stand for re-election; to become advisor

Chris Gibson, Ph.D., founder and Chair, will not seek re-election at 2026 Annual Meeting (June 2026).
March 25, 2026, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 7.01 item 9.01

Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out

Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.
February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Recursion Q4 revenue $35.5M; first AI-driven clinical validation in FAP; cash runway to 2028

Q4 revenue $35.5M (up from $4.5M YoY); net loss $108.1M vs $178.9M; cash $753.9M.
January 12, 2026, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Recursion releases updated investor presentation for JP Morgan Healthcare Conference

Presentation dated January 12, 2026, used at JP Morgan Healthcare Conference and investor meetings.
December 8, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction

75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.
November 26, 2025, 6:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Recursion issues 7.1M shares to Tempus AI for license fees; registers for resale

Issued 7,088,742 Class A shares to Tempus AI on Nov 24, 2025 as payment for annual license fees.
November 5, 2025, 6:59 PM ET leadership materiality 0.80 neutral item 2.02 item 5.02 item 7.01 item 9.01

Recursion appoints Najat Khan as CEO effective Jan 1, 2026; Q3 net loss $162.3M

Najat Khan succeeds Chris Gibson as CEO and President effective Jan 1, 2026; Gibson becomes Chairman.
October 29, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01

Roche exercises option for Recursion's Microglia Map; $30M fee

Roche exercised option for a first-of-its-kind whole genome map of brain immune cells (Microglia Map) from Recursion.
August 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02 item 8.01 item 9.01

Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone

Milestone triggered by initiation of GLP toxicology study on August 25, 2025.
August 5, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01

Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates

Announced $7 million milestone from Sanofi partnership for partnered discovery program.
July 8, 2025, 7:59 PM ET M&A materiality 0.65 positive item 3.02 item 7.01 item 8.01 item 9.01

Recursion acquires full ownership of oral ENPP1 inhibitor program from Rallybio

Buys Rallybio's 50% stake in ENPP1 JV, gaining full rights to REV102 for hypophosphatasia.
June 18, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Recursion Pharmaceuticals stockholders elect directors, approve exec comp, ratify auditor at 2025 meeting

Elected Zachary Bogue (242.3M for, 4.0M withheld), Zavain Dar (203.3M for, 42.9M withheld), Robert Hershberg (233.5M for, 12.8M withheld) as Class I directors.
June 10, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.05 item 7.01 item 9.01 ◈ Restructurings & Charges

Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges

Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
May 9, 2025, 7:59 PM ET other materiality 0.30 neutral item 8.01 item 9.01

Recursion registers 4.26M shares for resale by Tempus Labs under prior license agreement

Filed prospectus supplement to register 4,260,927 shares of Class A common stock for resale by Tempus Labs, Inc.
May 5, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused

Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).
March 18, 2025, 7:59 PM ET leadership materiality 0.55 positive item 5.02 item 7.01 item 8.01 item 9.01 ◈ executive_change ×2

Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board

Elaine Sun and Dr. Namandjé Bumpus appointed to Board effective March 15, 2025, expanding board from 8 to 10.
February 28, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027

Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.
January 13, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Recursion Pharmaceuticals releases updated investor presentation for JP Morgan Healthcare Conference

Investor presentation dated January 13, 2025 attached as Exhibit 99.1
December 17, 2024, 6:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Recursion registers 3.5M shares for resale by Tempus Labs as license fee payment

Recursion filed prospectus supplement to register 3,498,393 shares for resale by Tempus Labs.
December 3, 2024, 6:59 PM ET leadership materiality 0.55 neutral item 5.02

Recursion CFO Ben Taylor gets $5M equity grant, enhanced vesting on Exscientia awards

Ben Taylor (CFO) enters employment letter with Exscientia AI Ltd, base salary £400K/year.
November 27, 2024, 6:59 PM ET M&A materiality 0.75 neutral item 9.01

Recursion completes Exscientia acquisition; pro forma shows increased net losses

Total purchase price ~$635.9M; transaction closed Nov 20, 2024.
November 26, 2024, 6:59 PM ET M&A materiality 0.50 neutral item 3.02

Recursion issues 102.3M shares to close Exscientia acquisition

102,298,808 shares of Class A common stock issuable to Exscientia shareholders and option/RSU holders.
November 20, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 2.01 item 5.02 item 7.01 item 8.01 item 9.01 item 6.01 ◈ executive_change ×3◈ M&A Transactions

Recursion completes Exscientia acquisition; issues 102M shares, names new CFO

Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
November 13, 2024, 6:59 PM ET M&A materiality 0.85 positive item 8.01 item 9.01

Recursion & Exscientia shareholders approve combination; close expected Nov 20

Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.
November 13, 2024, 6:59 PM ET other material materiality 0.70 positive item 5.07

Recursion shareholders approve stock issuance for Exscientia acquisition

Shareholders voted 99.77% in favor (250.9M votes for) of issuing Class A common stock for the Exscientia acquisition.
November 6, 2024, 6:59 PM ET M&A materiality 0.65 neutral item 1.01 item 8.01 item 9.01

Recursion amends Exscientia acquisition to clarify post-closing board appointments

Amendment lets Exscientia designate one board member (subject to Recursion board approval) effective at closing; a second member if mutually agreed.
November 6, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track

Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.
October 2, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 7.01 item 9.01

FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma

FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
September 3, 2024, 7:59 PM ET other material materiality 0.75 neutral item 7.01 item 8.01 item 9.01

Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger

SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
August 28, 2024, 7:59 PM ET M&A materiality 0.60 positive item 8.01 item 9.01

Evotec commits ~11% Exscientia shares to Recursion deal; total committed ~53%

Evotec SE, holding ~11% of Exscientia shares, executed irrevocable undertaking on Aug 28 to vote in favor of Recursion acquisition.
August 8, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 2.02 item 3.02 item 5.02 item 7.01 item 9.01 ◈ executive_change

Recursion acquires Exscientia in stock deal; director Burrell resigns; Q2 results reported

Recursion to acquire Exscientia via UK scheme of arrangement; Exscientia shareholders get 0.7729 Recursion shares per share.
August 6, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01

Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee

Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.
June 27, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Recursion prices $200M public offering of 30.8M shares at $6.50 per share

Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.
June 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership

Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.
June 7, 2024, 7:59 PM ET other materiality 0.00 neutral item 5.07

Recursion annual meeting elects Class III directors, approves say-on-pay

Blake Borgeson, Ph.D. elected as Class III director with 165,914,956 votes for, 26,093,759 withheld.
May 24, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 4.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting

Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.
May 9, 2024, 7:59 PM ET other material materiality 0.75 negative item 2.02 item 4.01 item 7.01 item 9.01 ◈ Auditor Changes ×2◈ Earnings Releases

Recursion posts Q1 net loss $91.4M; replaces EY with PwC after material weakness

Net loss of $91.4M, up from $65.3M YoY; revenue $13.8M, up from $12.1M.
April 16, 2024, 7:59 PM ET leadership materiality 0.70 positive item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Recursion appoints Najat Khan as Chief R&D and Commercial Officer, joins board

Dr. Khan appointed Chief R&D Officer and Chief Commercial Officer; also elected Class II Director with term through 2026.
February 27, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Recursion reports Q4 net loss of $93M, cash $391.6M; '24 clinical data readouts planned

Net loss $93M in Q4 2023 vs $57.5M a year ago; full-year loss $328.1M vs $239.5M.
February 7, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change ×2

Recursion Pharma CBO Virani transitions to Senior Strategic Advisor; Kinn joins exec team

Dr. Shafique Virani stepped down as Chief Business Officer effective Feb 6, 2024, to become Senior Strategic Advisor.
January 31, 2024, 6:59 PM ET other materiality 0.10 neutral item 5.03 item 9.01 ◈ Governance Changes

Recursion Pharmaceuticals amends bylaws to enhance proxy disclosure and conform to Delaware law

Bylaw amendments enhance procedural mechanics and disclosure for stockholder director nominations and proposals (except Rule 14a-8).
January 8, 2024, 6:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Recursion Pharmaceuticals releases updated investor presentation for JPM Healthcare Conference

Presentation released on January 8, 2024, for use at JPM Healthcare Conference and investor meetings.
December 20, 2023, 6:59 PM ET other material materiality 0.55 positive item 7.01 item 9.01

Recursion partners with Enamine to create enriched screening libraries using MatchMaker predictions on 36B compounds

Up to 100 biological targets selected; Recursion's MatchMaker predicts protein-ligand interactions across Enamine's 36B REAL Space compounds.
December 15, 2023, 6:59 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

Recursion registers 3.2M shares of Class A common stock for resale by Tempus Labs

3,225,902 shares registered for resale by Tempus Labs as payment for initial license fee under Master Agreement.
November 9, 2023, 6:59 PM ET other material materiality 0.85 neutral item 1.01 item 2.02 item 3.02 item 7.01 item 9.01 ◈ Material Agreements ×2◈ Earnings Releases

Recursion posts Q3 net loss $93M, inks $160M Tempus data deal, restructures Bayer collaboration for oncology

Q3 net loss of $93.0M vs $60.4M prior year; revenue $10.5M down from $13.2M.
October 2, 2023, 7:59 PM ET other material materiality 0.55 positive item 7.01 item 8.01 item 9.01

Roche exercises oncology option under Recursion collaboration; triggers undisclosed fee

Roche exercised Validated Small Molecule Option for a Small Molecule Validation Program in a single oncology area.
September 5, 2023, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Recursion completes Phase 1 study for REC-3964; drug well tolerated, Phase 2 planned for 2024

Phase 1 study of REC-3964 in healthy volunteers completed; no serious adverse events reported.
August 11, 2023, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes

Recursion adopts annual Say-on-Pay vote after shareholder majority

At June 16, 2023 annual meeting, majority of votes favored annual advisory Say-on-Pay votes.